Advanced search
Publication Cover
Expert Review of Ophthalmology Volume 8, 2013 - Issue 3
Submit an article Journal homepage
30
Views
0
CrossRef citations to date
0
Altmetric
Perspective

Azithromycin use for trachoma control: lessons learned from Tanzania

Sheila K West Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA. [email protected]; Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA. [email protected]
&
Harran Mkocha Kongwa Trachoma Project, Kongwa, Tanzania; Kongwa Trachoma Project, Kongwa, Tanzania
Pages 245-253 | Published online: 09 Jan 2014

References

  • Taylor HR, Johnson SL, Prendergast RA, Schachter J, Dawson CR, Silverstein AM. An animal model of trachoma II. The importance of repeated reinfection. Invest. Ophthalmol. Vis. Sci. 23(4), 507–515 (1982).
  • West SK, Rapoza P, Muñoz B, Katala S, Taylor HR. Epidemiology of ocular chlamydial infection in a trachoma-hyperendemic area. J. Infect. Dis. 163(4), 752–756 (1991).
  • West S, Muñoz B, Bobo L et al. Nonocular chlamydia infection and risk of ocular reinfection after mass treatment in a trachoma hyperendemic area. Invest. Ophthalmol. Vis. Sci. 34(11), 3194–3198 (1993).
  • West S, Muñoz B, Lynch M et al. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet 345(8943), 155–158 (1995).
  • Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 342(8869), 453–456 (1993).
  • Tabbara KF, Abu-el-Asrar A, al-Omar O, Choudhury AH, al-Faisal Z. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology 103(5), 842–846 (1996).
  • Schachter J, West SK, Mabey D et al. Azithromycin in control of trachoma. Lancet 354(9179), 630–635 (1999).
  • Keenan JD, Ayele B, Gebre T et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin. Infect. Dis. 52(7), 883–888 (2011).
  • Muñoz B, Solomon AW, Zingeser J et al. Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children. Invest. Ophthalmol. Vis. Sci. 44(4), 1464–1469 (2003).
  • Basilion EV, Kilima PM, Mecaskey JW. Simplification and improvement of height-based azithromycin treatment for paediatric trachoma. Trans. R. Soc. Trop. Med. Hyg. 99(1), 6–12 (2005).
  • Initiative IT. Zithromax in the Elimination of Blinding Trachoma: a Program Manager’s Guide. Health TF (Ed.). International Trachoma Initiative, GA, USA (2010).
  • Bowman RJ, Sillah A, Van Dehn C et al. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Invest. Ophthalmol. Vis. Sci. 41(13), 4074–4079 (2000).
  • Gray RH, Wabwire-Mangen F, Kigozi G et al. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am. J. Obstet. Gynecol. 185(5), 1209–1217 (2001).
  • Muñoz B, Bobo L, Mkocha H, Lynch M, Hsieh YH, West S. Incidence of trichiasis in a cohort of women with and without scarring. Int. J. Epidemiol. 28(6), 1167–1171 (1999).
  • West SK, Munoz B, Turner VM, Mmbaga BB, Taylor HR. The epidemiology of trachoma in central Tanzania. Int. J. Epidemiol. 20(4), 1088–1092 (1991).
  • Fry AM, Jha HC, Lietman TM et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin. Infect. Dis. 35(4), 395–402 (2002).
  • Ayele B, Gebre T, House JI et al. Adverse events after mass azithromycin treatments for trachoma in Ethiopia. Am. J. Trop. Med. Hyg. 85(2), 291–294 (2011).
  • Stare D, Harding-Esch E, Munoz B et al. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia. Ophthalmic Epidemiol. 18(1), 20–29 (2011).
  • Batt SL, Charalambous BM, Solomon AW et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47(9), 2765–2769 (2003).
  • Gaynor BD, Holbrook KA, Whitcher JP et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Br. J. Ophthalmol. 87(2), 147–148 (2003).
  • Skalet AH, Cevallos V, Ayele B et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med. 7(12), e1000377 (2010).
  • Coles CL, Mabula K, Seidman JC et al. Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistance S. pneumoniae carriage in young children 6 months after treatment. Clin. Infect Dis. 56(11), 1519–1526 (2013).
  • Bhengraj AR, Vardhan H, Srivastava P, Salhan S, Mittal A. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India. Chemotherapy 56(5), 371–377 (2010).
  • West ES, Munoz B, Mkocha H et al. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest. Ophthalmol. Vis. Sci. 46(1), 83–87 (2005).
  • Campbell JP, Mkocha H, Munoz B, West SK. Randomized trial of high dose azithromycin compared to standard dosing for children with severe trachoma in Tanzania. Ophthalmic Epidemiol. 16(3), 175–180 (2009).
  • Campbell JP, Mkocha H, Munoz B, West SK. Two-day dosing versus one-day dosing of azithromycin in children with severe trachoma in Tanzania. Ophthalmic Epidemiol. 19(1), 38–42 (2012).
  • WHO. 3rd Global Scientific Meeting on Trachoma. WHO, Geneva, Switzerland (2010).
  • Solomon AW, Holland MJ, Alexander ND et al. Mass treatment with single-dose azithromycin for trachoma. N. Engl. J. Med. 351(19), 1962–1971 (2004).
  • Ray KJLT, Porco TC, Keenan JD et al. When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countries. PLoS Negl. Trop. Dis. 3, 458 (2009).
  • West SK, Munoz B, Mkocha H, Gaydos C, Quinn T. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Invest. Ophthalmol. Vis. Sci. 48(4), 1492–1497 (2007).
  • West SK, Munoz B, Mkocha H, Gaydos CA, Quinn TC. Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania. J. Infect. Dis. 204(2), 268–273 (2011).
  • Burton MJ, Holland MJ, Makalo P et al. Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities. PLoS Negl. Trop. Dis. 4(10), e835 (2010).
  • Yohannan J, Munoz B, Mkocha H et al. Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma? PRET Ziada Trial Results. JAMA Ophthalmol. 7, 1–6 (2013).
  • Gebre T, Ayele B, Zerihun M et al. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. Lancet 379(9811), 143–151 (2012).
  • Ssemanda EN, Levens J, Mkocha H, Munoz B, West SK. Azithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment rounds. PLoS Negl. Trop. Dis. 6(3), e1576 (2012).
  • Ssemanda EN, Munoz B, Harding-Esch EM et al.; PRET Project Team. Mass treatment with azithromycin for trachoma control: participation clusters in households. PLoS Negl. Trop. Dis. 4(10), e838 (2010).
  • Tabbara KF. Blinding trachoma: the forgotten problem. Br. J. Ophthalmol. 85(12), 1397–1399 (2001).
  • Frick KD, Lynch M, West S, Munoz B, Mkocha HA. Household willingness to pay for azithromycin treatment for trachoma control in the United Republic of Tanzania. Bull. World Health Organ. 81(2), 101–107 (2003).
  • Lynch M, West S, Muñoz B, Frick KD, Mkocha HA. Azithromycin treatment coverage in Tanzanian children using community volunteers. Ophthalmic Epidemiol. 10(3), 167–175 (2003).
  • Taylor PB, Burd EM, Tabbara KF. Monoclonal antibodies in the laboratory diagnosis of trachoma. Int. Ophthalmol. 12(1), 81–86 (1988).
  • West SK, Stare D, Mkocha H, Munoz B, Gaydos C, Quinn TC. Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma? Invest. Ophthalmol. Vis. Sci. 52(8), 6040–6042 (2011).
  • Keenan JD, Lakew T, Alemayehu W et al. Slow resolution of clinically active trachoma following successful mass antibiotic treatments. Arch. Ophthalmol. 129(4), 512–513 (2011).
  • Broman AT, Shum K, Munoz B, Duncan DD, West SK. Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania. Invest. Ophthalmol. Vis. Sci. 47(1), 99–104 (2006).
  • Allen SK, Semba RD. The trachoma menace in the United States, 1897–1960. Surv. Ophthalmol. 47(5), 500–509 (2002).
  • Taylor HR. Trachoma: a Blinding Scourge from the Bronze Age to the Twenty First Century. Centre for Eye Research, East Melbourne, Australia (2008).
  • Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull. World Health Organ. 65(4), 477–483 (1987).
  • Taylor HR, West SK, Katala S, Foster A. Trachoma: evaluation of a new grading scheme in the United Republic of Tanzania. Bull. World Health Organ. 65(4), 485–488 (1987).
  • Courtright P, Sheppard J, Schachter J, Said ME, Dawson CR. Trachoma and blindness in the Nile Delta: current patterns and projections for the future in the rural Egyptian population. Br. J. Ophthalmol. 73(7), 536–540 (1989).
  • Taylor HR, West SK, Mmbaga BB et al. Hygiene factors and increased risk of trachoma in central Tanzania. Arch. Ophthalmol. 107(12), 1821–1825 (1989).
  • West S, Lynch M, Turner V et al. Water availability and trachoma. Bull. World Health Organ. 67(1), 71–75 (1989).
  • Tielsch JM, West KP Jr, Katz J et al. The epidemiology of trachoma in southern Malawi. Am. J. Trop. Med. Hyg. 38(2), 393–399 (1988).
  • Taylor HR, Velasco FM, Sommer A. The ecology of trachoma: an epidemiological study in southern Mexico. Bull. World Health Organ. 63(3), 559–567 (1985).
  • Thylefors B, Négrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull. World Health Organ. 73(1), 115–121 (1995).
  • WHO. Global Elimination of Blinding Trachoma. World Health Assembly, Geneva, Switzerland (1998).
  • Reacher MH, Muñoz B, Alghassany A, Daar AS, Elbualy M, Taylor HR. A controlled trial of surgery for trachomatous trichiasis of the upper lid. Arch. Ophthalmol. 110(5), 667–674 (1992).
  • Mariotti SP, Pascolini D, Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br. J. Ophthalmol. 93(5), 563–568 (2009).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.